| DC7488 |
RO4987655
|
RO4987655(CH-4987655) is an orally active small molecule, targeting mitogen-activated protein kinase kinase 1 (MAP2K1/MEK1 IC50=5.2 nM), with potential antineoplastic activity. |
| DC8473 |
Vacquinol-1
|
Vacquinol-1 is an activator of MKK4-dependent macropinocytotic cell death in glioblastoma cells. |
| DC7243 |
U0126
|
U0126-EtOH(U-0126) is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD098059. |
| DC1099 |
Trametinib
|
Trametinib is a highly specific and potent MEK1 and MEK2 inhibitor with IC50 of 0.92 nM and 1.8 nM, respectively. |
| DC7308 |
TAK-733
|
TAK-733 is a potent and selective MEK allosteric site inhibitor for MEK1 with IC50 of 3.2 nM, inactive to Abl1, AKT3, c-RAF, CamK1, CDK2, c-Met, etc. |
| DC7808 |
Refametinib (BAY86-9766)
|
Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively. |
| DC1056 |
PD0325901 (Mirdametinib)
|
PD0325901 (PD325901) is selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM. |
| DC5100 |
PD 98059
|
PD 98059 is a selective inhibitor of MEK and blocker of MAPK |
| DC7723 |
OTS964， OTS 964
|
OTS964 is a novel TOPK(T–lymphokine-activated killer cell–originated protein kinase) inhibitor. |
| DC4177 |
Cobimetinib(GDC-0973; XL518)
|
GDC-0973 is a potent, highly selective inhibitor of mitogen-activated protein kinase kinase, also known as MEK, a serine/threonine kinase that is a component of the RAS/RAF/MEK/ERK pathway. |
